- Home
- KURA vs VINP Comparison
KURA vs VINP Comparison
Compare KURA & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KURA | VINP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 807.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KURA | VINP |
|---|---|---|
| Price | $9.91 | $13.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $25.00 | $13.50 |
| AVG Volume (30 Days) | ★ 1.6M | 44.2K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | ★ 4.61% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | $104,029,000.00 | ★ $180,689,571.00 |
| Revenue This Year | $138.16 | $67.12 |
| Revenue Next Year | $67.37 | $15.14 |
| P/E Ratio | ★ N/A | $25.65 |
| Revenue Growth | N/A | ★ 100.47 |
| 52 Week Low | $5.41 | $8.66 |
| 52 Week High | $12.49 | $13.25 |
Technical Indicators
Market Signals| Indicator | KURA | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 64.51 |
| Support Level | $10.17 | $12.04 |
| Resistance Level | $10.78 | $13.25 |
| Average True Range (ATR) | 0.60 | 0.32 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 9.47 | 78.57 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.